Susquehanna Fundamental Investments LLC Takes $593,000 Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Susquehanna Fundamental Investments LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 44,785 shares of the biotechnology company's stock, valued at approximately $593,000. Susquehanna Fundamental Investments LLC owned about 0.15% of AnaptysBio as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC grew its stake in shares of AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after buying an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in AnaptysBio during the 4th quarter worth approximately $40,000. AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 4,237 shares during the period. Virtus ETF Advisers LLC increased its stake in AnaptysBio by 24.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 5,360 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. HC Wainwright reissued a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a research note on Tuesday, March 4th. Johnson Rice reaffirmed a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Finally, Guggenheim reiterated a "buy" rating on shares of AnaptysBio in a report on Monday, March 3rd. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and an average target price of $33.63.

AnaptysBio Stock Down 2.4 %

Shares of ANAB stock opened at $21.19 on Friday. The business's fifty day moving average is $18.24 and its 200 day moving average is $19.12. The stock has a market cap of $626.67 million, a price-to-earnings ratio of -3.49 and a beta of -0.20. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. Equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has authorized a stock repurchase plan on Monday, March 24th that authorizes the company to buyback $75.00 million in shares. This buyback authorization authorizes the biotechnology company to repurchase up to 13.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.